Post‐marketing surveillance of quetiapine fumarate extended‐release tablets in patients with bipolar depression
Abstract Aim This study aimed to verify the real‐world efficacy and safety of quetiapine fumarate extended‐release tablets (Bipresso® 50 mg and 150 mg; marketing authorization holder is KYOWA Pharmaceutical Industry Co., Ltd., Osaka, Japan) in patients with bipolar depression. Methods We performed a...
Saved in:
| Main Authors: | , , , |
|---|---|
| 格式: | 圖書 |
| 出版: |
Wiley,
2024-06-01T00:00:00Z.
|
| 主題: | |
| 在線閱讀: | Connect to this object online. |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
因特網
Connect to this object online.3rd Floor Main Library
| 索引號: |
A1234.567 |
|---|---|
| 復印件 1 | 可用 |